Traditional combination ART consists of 2 nucleoside reverse transcriptase inhibitors + 1 protease inhibitor; this prospective study of 274 pregnant women infected with HIV compared their viral load near delivery after receiving traditional cART.
IDWeek 2012: HIV
A pilot study presented at IDWeek 2012 to assess durability of HIV-1 virologic suppression in subjects who switched from HAART regimen to lopinavir/ritonavir monotherapy failed to maintain viral suppression in a sufficient number of subjects to continue the study, investigators reported.
A study reported at IDWeek 2012 comparing the efficacy of different statins when co-administered with highly active antiretroviral therapy in patients with HIV found no significant difference in LDL reduction.
A study of patients with chronic hepatitis C and a history of hepatocellular carcinoma treated with pegylated interferon alpha-2b plus ribavirin showed a high risk of recurrence, according to data presented at IDWeek 2012.
The antiretroviral combination known as “the Quad” demonstrated comparable efficacy and favorable tolerability to Atripla in adherent treatment-naïve patients with HIV infection, according to a a study presented at IDWeek 2012.
Virologic failure of second-line combination ART was less likely if patients were switched with an HIV RNA viral load (VL) <400c/mL, according to a study presented at IDWeek 2012.
The pharmacokinetics across combinations of concomitant telaprevir and efavirenz or atazanavir/ritonavir-based regiments in hepatitis C (HCV)/HIV co-infected patients were comparable and consistent with those observed historically in HCV mono-infected patients, according to Varun Garg, PhD, from Vertex Pharmaceuticals, Inc., Cambridge, MA, at IDWeek 2012.
Efavirenz-, atazanavir + ritonavir-, and raltegravir-containing regimens are compatible for use with direct acting antivirals, stated Sonia Vibhakar, PharmD, from The Ruth M. Rothstein CORE Center, Chicago, IL, and colleagues, at IDWeek 2012.
Want to read more?
Please login or register first to view this content.